





























	 Cadmium	 (Cd)	 has	 been	 classified	 as	 a	 human	 carcinogen.	 The	World	 Health	 Organization
(WHO)	reported	that	the	concentration	of	Cd	in	the	environment	has	rapidly	increased	in	the
last	 few	 years.	 In	 many	 epidemiological	 studies,	 the	 correlation	 between	 environmental
exposure	 of	 humans	 to	 Cd	 and	 diseases	 such	 as	 stroke,	 ischemia,	 renal	 and	 hepatic
dysfunction,	 anemia,	 osteoporosis	 and	 diabetes	 has	 been	 discussed.	 For	 the	 treatment	 of
heavy	metal	intoxications	a	therapy	with	chelating	agents	has	been	applied.	A	chelating	agent
is	 a	 compound	 that	 binds	 the	 toxic	 metal	 ion	 thus	 promoting	 its	 excretion	 by	 the	 living
organisms.	 Recently,	 it	 has	 been	 found	 that	 Cd‐induced	 toxicity	 is	 a	 result	 of	 formation	 of
reactive	oxygen	species	(ROS).	These	results	increased	the	interest	towards	the	antioxidants
as	 possible	 agents	 for	 the	 treatment	 of	 Cd‐induced	 organ	 toxicity.	 Herein,	 we	 present











Cadmium	 (Cd)	 is	 a	 toxicant,	 classified	 as	 a	 human	
carcinogen	by	the	International	Agency	for	Research	on	Cancer	
[1].	According	 to	 the	data	provided	by	 the	WHO,	 the	daily	Cd	





cause	 severe	 organ	 toxicity.	When	 accumulated	 in	 the	body	 it	
induces	hepatotoxicity	[4],	renal	dysfunction	[5,6],	distortion	of	
the	 reproductive	 function	 [7,8]	 and	 cardiovascular	 injury	 [9‐
14].	
Compounds	that	possess	low	toxicity,	good	absorbability	by	
the	 gastrointestinal	 tract	 and	bind	 toxic	metal	 ions	have	been	







copper	 (Cu)	 from	 cytoplasmic	 proteins	 and	 metalloenzymes	
[19].	 Free	 iron	 and	 copper	 ions	 participate	 in	 Fenton	 type	
reactions	 leading	 to	 the	 generation	 of	 ROS	 [19‐21].	 Other	
possible	 mechanism	 for	 Cd‐induced	 oxidative	 stress	 includes	
direct	interaction	of	Cd	with	SH	groups	of	the	thiols	[20,21].	In	
the	 last	 years	 enormous	data	 regarding	 the	 application	of	 the	
antioxidants	for	the	treatment	of	Cd‐induced	toxicity	have	been	
published	[3].	
Herein	 we	 present	 a	 summary	 of	 the	 antioxidants	 and	
chelating	 agents	 screened	 on	 animal	 models	 to	 decrease	 Cd	
concentrations	in	the	body	and	to	prevent	Cd‐induced	oxidative	
stress.	The	data	presented	 in	 this	 review	comprise	 the	period	
1992‐2012	years.	Discussion	of	the	antioxidants	and	chelating	
agent	 tested	 to	 inhibit	 Cd‐induced	 hepatotoxicity,	 renal	






The	 liver	 and	 kidneys	 are	 critical	 organs	 in	 Cd‐induced	
intoxications.	 When	 accumulated	 in	 the	 liver	 Cd	 induces	
inflammatory	 cell	 infiltrations,	 dilation	 of	 sinosoids	 and	








The	 antioxidants	 tested	 on	 animal	models	 to	 prevent	 Cd‐
induced	 hepatotoxicity	 are	 presented	 in	 Tables	 1	 and	 2.	 As	
could	be	seen	from	the	data,	presented	in	both	tables,	 there	is	


































































































































































































Cd‐induced	 oxidative	 stress	 in	 the	 liver	 is	 monitored	 by	 the	
analysis	 of	 superoxide	 dismutase	 activity	 (SOD),	 catalase	
activity	 (CAT),	 gluthathione	 level	 (GSH)	 and	 level	 of	 lipid	
peroxidation	 (LPO),	 expressed	 as	 thiobarbituric	 acid	 reactive	
species	(TBRAS)	or	malondyaldehyde	(MDA).	Cd	decreases	the	
level	of	GSH,	and	the	activity	of	SOD	and	CAT	in	the	liver	of	Cd‐
intoxicated	 animals	 and	 induces	 a	 significant	 increase	 of	LPO.	
All	antioxidants	studied	have	been	demonstrated	to	prevent	in	






The	 antioxidants,	 screened	 on	 animal	 models	 for	 the	
































































































































Among	 the	 antioxidants,	 presented	 in	 the	 Table	 1,	 alpha	
lipoic	acid	(α‐LA),	curcumin,	Mn‐curcumin	complex,	resveratol	
and	 melatonin	 have	 been	 shown	 not	 to	 prevent	 Cd‐
accumulation	in	the	liver	of	Cd‐treated	animals	[25‐28].		
Alpha	 lipoic	 acid	 (α‐LA),	 resveratol	 and	melatonin	did	not	
affect	Cd‐induced	decrease	of	GSH	level	in	the	liver,	suggesting	
that	 these	 antioxidants	 might	 not	 be	 the	 best	 choice	 for	 the	
treatment	of	Cd‐induced	oxidative	stress	in	the	liver	of	animals,	
subjected	 to	 subacute	 and	 acute	Cd‐intoxications	 [25,28].	Mn‐
curcumin	complex	recovers	GSH	level	in	the	liver	but	the	effect	
of	this	antioxidant	on	the	trace	element	homeostasis	especially	
Fe	 and	 Cu	 should	 be	 taken	 into	 account	 when	 Mn‐curcumin	
complex	is	applied	for	the	therapy	of	Cd‐induced	hepatotoxicity	
[27].		
Diallyl	 tetrasulfide	 [29,30],	 endomorophin	 1	 [31],	 taurine	
[22]	and	carnosine	[23]	have	been	demonstrated	to	prevent	Cd	
accumulation	 in	 the	 liver	 of	 animals,	 subjected	 to	 acute	 and	





to	 improve	 the	 level	 of	 GSH	 in	 male	 rats,	 subjected	 to	 acute	
intoxication	with	Cd(II)	 salt	 [32].	Panax	ginseng,	ascorbic	acid	
and	 garlic	 also	 improve	 the	 total	 antioxidant	 capacity	 of	 the	
liver	 in	 Cd‐treated	 animals	 [33,34].	 Detail	 histological	 studies	
about	 the	effect	of	 these	antioxidants	on	the	 liver	morphology	










homeostasis	 should	 be	 considered	 when	 this	 antioxidant	 is	
utilized	 for	 the	 treatment	 of	 Cd‐induced	 hepatotoxicity.	
Organoselenocyanates	 [39]	 have	 been	 also	 effective	 in	
restoring	 the	 activity	 of	 CAT	 in	 the	 liver	 of	 Cd‐intoxicated	
animals	but	the	compounds	do	not	recover	SOD	values.	Among	
the	 antioxidants	 screened	 on	 animals	 subchronically	 or	













































































Abbreviations:	 Mi‐ADMS:	 monoisoamyl	 meso‐2,3‐dimercaptosuccinate;	 MeBLDTC:	 N‐(4‐methylbenzyl)‐4‐O‐(beta‐D‐galactopyranosyl)‐D‐glucamine‐N‐
carbodithioate;	 DDC:	 diethyl	 dithiocarbamate;	 DMDC:	 dimethyl	 dithiocarbamate;	 CYCLAM:	 1,4,8,11‐tetraazacyclotetradecane;	 TACPD:	 1,4,8,12‐
tetraazacyclopentadecane;	 DMSA:	 2,3	 dimercaptosuccinic	 acid;	 DMPS:	 2,3‐dimercapto‐1‐propane	 sulfonate;	 Mi‐PDMA:	 meso‐2,3‐dimercaptosuccinic	 acid	




N‐carbodithioate	 (MeBTDTC)	 and	 monoisoamyl	 meso‐2,3‐
dimercaptosuccinate	 (Mi‐ADMS)	 on	 Cd	 concentration	 in	
Cd‐treated	animals	has	demonstrated	 that	 the	chelating	agent	
MeBTDTC	 reduces	 more	 effectively	 the	 concentration	 of	 the	
toxic	 metal	 in	 the	 liver	 of	 animals,	 subjected	 to	 acute	 Cd‐
intoxication	but	 could	not	be	applied	orally	 in	 contrast	 to	Mi‐
ADMS	(Table	3)	 [44].The	effect	of	 the	chelating	agents	diethyl	
dithiocarbamate	 (DDC),	 dimethyl	 dithiocarbamate	 (DMDC),	
1,4,8,11‐tetraazacyclotetradecane	 (CYCLAM),	 1,4,8,12‐tetraaza	
cyclopentadecane	 (TACPD),	 2,3‐dimercaptosuccinic	 acid	
(DMSA),	 and	 2,3‐dimercapto‐1‐propane	 sulfonate	 (DMPS)	 on	
Cd	concentration	in	the	liver,	kidney	and	brain	of	mice,	exposed	
to	 Cd‐intoxication	 has	 been	 compared.	 The	 results	 by	
Srivastava	 et	 al.	 demonstrate	 that	 DMSA	 and	 DMPS	 are	most	
effective	 in	 reducing	 Cd	 [45],	 compared	 to	 DDC,	 DMDC,	
CYCLAM,	 TACPD.	 DMSA	 and	 DMPS	 however	 are	 hydrophilic	
compounds	 and	 their	 ability	 to	 bind	 the	 toxic	 metal	 ion,	
accumulated	in	the	intracellular	space	is	limited.	
The	 meso‐2,3‐dimercaptosuccinic	 acid	 mono‐N‐
alkylamides:	 Mi‐PDMA	 (meso‐2,3‐dimercaptosuccinic	 acid	
monoisopropylamide);	 Mi‐BDMA	 (meso‐2,3‐dimercapto‐
succinic	 acid	 monoisobutylamide)	 and	 Mi‐ADMA	 (meso‐2,3‐





Our	 studies	 have	 demonstrated	 that	 the	 polyether	
ionophorous	 antibiotic	 monensin	 (applied	 p.o.	 as	 tetraethyl	
ammonium	salt)	to	mice,	subjected	to	subacute	Cd‐intoxication	
reduces	the	concentration	of	the	toxic	metal	ion	in	the	liver	up	
to	 50	 %.	 Furthermore	 this	 chelating	 agent	 abolished	 Cd‐
induced	alterations	 in	 iron	homeostasis	and	recovered	Cu	and	
Zn	 levels.	The	data	 from	 the	histopathological	 studies	showed	
that	monensin	attenuated	Cd‐induced	inflammation	in	the	liver	














cases	 of	 metal	 intoxications.	 Cd	 has	 been	 shown	 to	 induce	
alterations	in	creatinine	(CR)	and	urea	in	the	urine	and	serum	
of	 Cd‐intoxicated	 animals	 [50].	 A	 decrease	 of	 the	 level	 of	 the	
antioxidant	enzymes	and	GSH	accompanied	with	an	increase	of	
the	 LPO	 in	 the	 kidneys	 of	 Cd‐intoxicated	 animals	 has	 been	
reported	 [51,52].	 On	 the	 morphological	 level	 Cd	 induces	
swelling	 of	 the	 epithelial	 cells	 of	 the	 renal	 tubules;	
degeneration	 and	 thickening	 of	 the	 basement	 membrane.	
Necrosis	 of	 the	 proximal	 renal	 tubules	 has	 been	 reported	 in	
animals,	 subjected	 to	 acute	 Cd‐intoxication	 [52].	 The	
antioxidants	 tested	 in	 the	 period	 1992‐2012	 years	 for	 the	
treatment	 of	 Cd‐induced	 renal	 dysfunction	 in	 animals,	
subjected	 to	 acute	 Cd‐intoxication,	 are	 presented	 in	 Table	 4.	
Diallyl	 tetrasulfide	 recovers	 the	 level	 of	 CR	 and	 urea	 in	 the	
serum	 and	 urine	 of	 Cd‐intoxicated	 rats.	 The	 antioxidant	 has	
been	 demonstrated	 to	 act	 as	 a	 chelating	 agent,	 reducing	 the	
concentration	of	 the	toxic	metal	 ion	by	70	%	compared	to	 the	
normal	control	[30].		
Garlic	 and	 onion	 extracts	 also	 effectively	 restore	 the	 total	
antioxidant	 capacity	 of	 the	 kidneys	 of	 Cd‐intoxicated	 animals	
[50].		
The	 honey	 bee,	 taurine,	 vitamin	 C	 and	 isoquercetin	 have	
been	shown	to	improve	the	antioxidant	defense	in	the	kidneys	
of	 animals,	 exposed	 to	 acute	 Cd‐intoxication	 [51‐53].	 Taurine	
and	 vitamin	 C	 have	 been	 demonstrated	 to	 recover	 CR	
concentration	 in	 the	 serum	 of	 mice,	 subjected	 to	 acute	 Cd‐
intoxication.	 Both	 antioxidants	 decrease	 MDA	 level,	 increase	
GSH	 and	 inhibit	 the	 accumulation	 of	 Cd	 in	 the	 kidneys.	 The	
histopathalogical	 analysis	 of	 kidneys	 of	 mice	 treated	 with	
taurine	 and	 Vitamin	 C	 prior	 to	 Cd‐intoxication	 demonstrates	
that	 the	 antioxidants	 preserve	 the	 normal	 renal	 architecture.	
Considering	that	Vitamin	C	is	an	oral	drug	it	might	be	the	best	
choice	 for	 the	 treatment	 of	 acute	 Cd‐intoxication	 [52].	 Caffeic	
acid	 also	 reduces	 Cd	 in	 the	 kidneys	 of	 animals,	 exposed	 to	
subacute	Cd‐intoxication	[54].		
Analysis	of	the	effect	of	caffeic	acid	on	Cd‐induced	elevation	
of	 Zn	 concentration	 in	 kidneys	 of	 Cd‐treated	 animals	






























































































































































































































































































Abbreviations:	Monoaralkyl	 esters	 of	 meso‐2,3‐dimercaptusuccinic	 acid:	 HOOCCH(SH)CH(SH)COOR,	 where	 R	 =	 phenylethyl	 (CH2)2C6H5,	 MPhEDMS;	 R	 =	 3‐
phenylpropyl	 ((CH2)3C6H5),	 MPhPDMS;	 and	 R	 =	 2‐phenoxyethyl	 (CH2)2OC6H5,	 MPhOEDMS;	 Triethylenetetramine	 dihydrochloride	 (TRIEN),	 Tris(2‐
aminoethyl)amine	trihydrochloride	(TREN),	Tetraethylenepentamine	pentahydrochloride	(TETRAEN),	Pentaethylenehexamine	hexahydrochloride	(PENTAEN);	













The	 antioxidants	 screened	 on	 animals,	 exposed	 to	
subchronic	 and	 chronic	 Cd‐intoxications,	 are	 summarized	 in	
Table	5.	
N‐acetylcysteine	 (NAC)	 salt	 is	 effective	 in	 improving	 renal	




E	 have	 been	 demonstrated	 to	 recover	 CR	 and	 urea	 levels	 in	
serum	 and	 urine	 in	 animals,	 subjected	 to	 subchronic	 Cd‐
intoxication	[57‐60].	Furthermore,	these	antioxidants	decrease	
LPO	in	the	kidneys	and	improve	GSH	and	antioxidant	enzymes	
levels.	 The	 histopatological	 analysis	 of	 the	 renal	 tissue	 of	 Cd‐
treated	 animals,	 receiving	 NGN	 or	 QE	 reveals	 that	 these	
antioxidants	preserve	the	normal	renal	architecture	[57‐60].		
The	 herbal	 adaptogens:	 Withania	 somnifera,	 Ocimum	
sanctum,	 Asperagus	 recemosus,	 Andrographis	 paniculata,	
Asphaltum	 panjabinum	 (Shilajith),	 Gymnema	 sylvestre,	
Spirulina	 platensis,	 and	 Panex	 ginseng	 have	 been	 tested	 to	
prevent	Cd	bioaccumulation	 in	 chicks,	 exposed	 to	 chronic	Cd‐
intoxication	[61].	The	herbal	adaptogens	Asperagus	recemosus	
and	 Andrographis	 paniculata,	 applied	 p.o.,	 reduce	 Cd	
concentration	 in	 kidney	 by	 50%	 compared	 to	 the	 control;	
inhibit	 LPO,	 and	 recover	GSH	 level.	 CR	values	 in	 the	 serum	of	





R	 =	 phenylethyl	 ((CH2)2C6H5),	MPhEDMS;	 R	 =	 3‐phenylpropyl	
((CH2)3C6H5),	 MPhPDMS;	 and	 R	 =	 2‐phenoxyethyl	
((CH2)2OC6H5).	 MPhOEDMS)	 of	 meso‐2,3‐dimercaptusuccinic	
acid	 have	 been	 effective	 in	 reducing	 the	hepatic	 and	 renal	 Cd	
concentration	 in	 Cd‐intoxicated	 rats,	 but	 no	 information	
regarding	 the	 effect	 of	 the	 chelating	 agents	 on	 the	 trace	
elements	 homeostasis	 has	 been	 presented.	 Furthermore,	 the	
esters	of	DMSA	have	been	administrated	i.p.,	which	could	be	a	
disadvantage	 of	 these	 agents	 over	 others	 chelators	 for	 the	
treatment	of	Cd‐intoxication	(Table	6)	[64].	
Among	 the	 chelating	 agents,	 the	 polyamines:	
triethylenetetraamine	 dihydrochloride	 (TRIEN),	 tris(2‐amino	
ethyl)amine	trihydrochloride	(TREN),	tetraethylene	pentamine	
pentahydrochloride	 (TETRAEN),	 and	 pentaethylene	 hexamine	
hexahydrochloride	(PENTAEN)	increase	Cd	in	 the	urine	of	Cd‐
exposed	 rats	 (Table	 5)	 [65].	Oliguria	 and	 anuria	 induced	 as	 a	
result	 of	 the	 application	 of	 these	 chelating	 agents	 have	 been	




from	 intracellular	 deposits.	 Therefore	 this	 agent	 is	 not	 very	
suitable	for	the	treatment	of	chronic	Cd‐intoxication	[46].	
The	chelating	agents	alpha‐mercapto‐beta‐(2‐furyl)	acrylic	
acid	 (MFA),	 alpha‐mercapto‐beta‐(5‐sodiumsulfonate,	 2‐furyl)	
acrylic	 acid	 (MSFA)	 and	 alpha‐mercapto‐beta‐(5‐acetoxy	





















































































Cd	 induces	 reduction	of	 sperm	motility,	 testosterone,	 3‐β‐
hydroxysteroiddehydrogenase	(3‐β‐HSD),	17‐β‐hydroxysteroid	
dehydrogenase	 (17‐β‐HSD)	 and	 an	 increase	 of	 the	percentage	
of	 abnormal	 sperm	 in	 animals,	 subjected	 to	 Cd	 intoxication.	
Histopathological	 analysis	 of	 testicular	 tissue	 of	 animals,	
administrated	 Cd,	 reveals	 that	 the	 toxic	 metal	 causes	 severe	
lesions	 in	 the	 form	 of	 diffuse	 necrosis	 affecting	 the	 germinal	
layer	 in	 the	 seminiferous	 tubules	 and	 interstitial	 tissue	 [70].	
Higher	 levels	 of	 lipid	 peroxidation	 in	 testes	 compared	 to	 the	
normal	control	have	been	reported	in	animals,	receiving	Cd.	Cd	









The	 antioxidants,	 screened	 on	 animal	 models	 for	 the	
treatment	 of	 oxidative	 stress	 in	 testes	 of	 animals,	 exposed	 to	
acute	 Cd‐intoxication,	 are	 summarized	 in	 Table	 7.	 Vitamins	 C	
and	 E	 alone	 or	 in	 combination,	 applied	 concurrent	 with	 Cd‐
intoxication	 have	 been	 shown	 to	 restore	 testosterone	 and	
testicular	 key	 androgenic	 enzymes	 3‐β‐hydroxysteroid	
dehydrogenase	 and	 17‐β‐hydroxysteroid	 dehydrogenase	
[71,72].	Depending	 on	 the	 dose	 of	 Cd,	 Vitamins	 C	 and	E	 have	
been	demonstrated	to	recover	partially	or	completely	the	total	








The	 antioxidants	 tested	 on	 Cd‐induced	 oxidative	 stress	 in	
animals,	exposed	to	subchronic	and	chronic	Cd	intoxication,	are	
presented	in	Table	8.	
Vitamin	 E	 and	 β‐carotene	 improve	 some	 hematological	
paramets	 (Hb,	 TEC,	 TLC)	 in	 rats,	 subjected	 to	 subchronic	 Cd‐	
intoxication	and	significantly	recover	sperm	quality	[80,81].	α‐
tocopherol	 reduces	 the	degree	of	necrosis	of	 the	 seminiferous	
tubules	induced	by	2	mg/kg	b.w.	Cd(II)	chroride,	injected	i.p.	in	
rats	 for	 5	 weeks	 [78,79].	 The	 antioxidant	 however	 has	 been	
demonstrated	not	 to	 have	protective	 effect	 in	 higher	 doses	 of	
Cd(II)	chloride	[80]	and	applied	before	Cd‐intoxication.		
α‐Lipoic	 acid,	 applied	 along	 with	 Cd,	 also	 recovers	
testicular	 key	 androgenic	 enzymes	 and	 preserves	 the	 normal	
testicular	architecture	[81].		
Among	the	antioxidants,	screened	on	animal	models	for	the	
treatment	 of	 Cd‐induced	 toxicity	 in	 the	 testes	 of	 animals	
exposed	 to	 subchronic	 or	 chronic	 Cd‐intoxication,	 hesperetin	
(HP),	 diallyl	 tetrasulfide	 (DTS)	 and	 α‐tocopherol	 possess	
chelating	 effect,	 reducing	 the	 concentration	 of	 toxic	metal	 ion	






The	 chelating	 agents	 screened	 on	 animal	 models	 for	 the	
treatment	 of	 Cd‐induced	 toxicity	 in	 testes	 are	 summarized	 in	
Table	 9.	 Diethyldithiocarbamate	 (DED)	 alone	 decreases	 Cd	
concentration	in	testes,	but	redistribution	of	the	toxic	metal	ion	
to	 the	 kidneys	 and	 brain	 has	 been	 observed	 [91,92].	 The	
combinations	 of	 DED	 and	 N‐benzyl‐D‐glucamine	 dithio	
carbamate	 (BGD)	 or	 DED	 and	 N‐p‐isopropylbenzyl‐D‐
glucaminedithiocarbamate	 (PBGD)	 diminish	 Cd	 level	 in	 testes	
without	 causing	 its	 redistribution	 in	 other	 tissues	 [91,92].	
However,	 these	 combinations	 of	 the	 chelating	 agents	 increase	
Cd	 concentration	 in	 the	 blood	 and	 Cd	 distribution	 in	 the	 red	
blood	cells	[91,92].	Disulfiram	(DSF)	has	been	demonstrated	to	





are	 ineffective	 in	 restoring	 the	 SOD	 activity	 and	 the	 level	 of	
ascorbic	 acid,	 induced	 by	 5	 mg/kg	 Cd(II)	 chloride	 [94].	
Diphenyl	diselenide	applied	s.c.	30	min	after	Cd	administration	
in	 mice	 elevates	 Cd‐induced	 injury	 in	 the	 testes,	 but	 when	
administrated	at	higher	dose	 (100	μmol/kg),	 applied	alone	or	
together	 with	 2,3‐dimercapto‐1‐propanesulfonic	 acid	 (DMPS)	


















































































































































































































































Dose	 Animal	model Effect Ref.


























































































Our	 results	have	demonstrated	 that	monensin	 (applied	 as	
tetraethylammonium	 salt)	 reduces	 Cd	 concentration	 in	 the	
testes	of	Cd‐treated	mice	by	50	%	compared	to	the	control.	The	
administration	of	the	chelating	agent	to	the	Cd‐intoxicated	mice	






Cd	 is	 a	 vascular	 toxicant	 that	 induces	 hypertension	 and	
myocardial	 hypertrophy.	 The	 generation	 of	 ROS	 either	 by	
affecting	Fe	homeostasis	or	NO	level	in	the	endothelial	cells	has	






The	 combination	 of	 coenzyme	 Q(10)	 and	 Vitamin	 E	 has	
been	 demonstrated	 to	 reverse	 Cd‐induced	 alterations	 in	 the	






The	 combination	 of	 α‐lipoic	 acid	 and	 melatonin	 applied	
along	with	 the	 Cd	 treatment	 also	 inhibits	 Cd‐induced	 cardiac	
impairment	 in	 rats,	 subjected	 to	 subchronic	 Cd‐intoxication	
[102].	
Vitamin	 C	 and	 taurine,	 applied	 before	 Cd‐intoxication,	
decrease	 Cd	 accumulation	 in	 the	 heart	 of	 mice,	 exposed	 to	
subacute	 Cd‐intoxication.	 Vitamin	 C	 is	 more	 effective	 than	


















metal	 ions.	 To	 the	best	 of	 our	 knowledge	 however	 this	 is	 the	
first	 review	 that	 summarizes	 the	 literature	 information	
published	in	the	last	20	years	for	the	antioxidants	and	chelating	
agents,	 tested	 on	 animal	 models	 for	 the	 treatment	 of	 Cd‐
induced	organ	toxicity.	Detailed	information	regarding	the	Cd‐




humans,	 exposed	 to	 Cd‐intoxication.	 Based	 on	 the	 data,	
presented	 in	 this	 paper,	 it	 could	 be	 concluded	 that	 the	
simultaneous	 application	 of	 antioxidants	 and	 chelating	 agents	
could	 be	 a	 good	 approach	 for	 the	 treatment	 of	 Cd‐induced	
organ	 toxicity.	 In	 order	 to	 identify	 the	 best	 antioxidant	 and	
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